ArticleThoracic cancer2015

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.

Jianya Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.